Anti-IgE treatment for disorders other than asthma

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.

Original languageEnglish
Article number152
JournalFrontiers in Medicine
Volume4
Issue numberSEP
DOIs
StatePublished - 2017

Keywords

  • Allergy
  • Asthma
  • Immunotherapy
  • Omalizumab
  • Urticaria

Fingerprint

Dive into the research topics of 'Anti-IgE treatment for disorders other than asthma'. Together they form a unique fingerprint.

Cite this